Chemogenetic arrays are focused collections of drug-like molecules targeted towards specific receptor families and pre-optimised to increase robustness and bioavailability in man
Peakdale Molecular announces the enhancement of its drug discovery capabilities through the introduction of Peakfinder chemogenetic arrays - focused collections of drug-like molecules targeted towards specific receptor families and pre-optimised to increase robustness and bioavailability in man.
Peakfinder chemogenetic arrays are designed to enhance receptor-ligand interactions within different but closely related families of targets, as previously exemplified by the Peakdale GPCR array.
Based on predictive models, the compounds are frontloaded with beneficial properties to provide them with a superior starting point for hit discovery resulting in faster, more cost-effective lead optimisation.
The latest Peakdale array will be targeted toward protein kinases, a highly regulated family of enzymes that play a central role in most critical cellular processes.
The diversity of these arrays is designed to achieve drug selectivity within this important class of drug targets to modulate therapeutically relevant signalling pathways.
Peakfinder arrays are designed using Peakradar, a computer-aided drug design tool which incorporates information from Admet profiles, hERG-free solubilising groups and 3D-Qsar models to direct the synthesis of focused arrays with a high-level of compound diversity.
The arrays build on Peakdale's core strengths and passion for innovative synthetic chemistry using proprietary chemistry capabilities and privileged pharmacophore scaffolds.
Commenting on the announcement, Terry Hart, medicinal chemistry services director: "The introduction of peakfinder chemogenetic arrays will help place us at the forefront as a provider of medicinal chemistry products and services.
"They offer a significant advantage to our customers as they have critical Admet functionality built-in and are therefore expected to produce better leads for medicinal chemists to work on allowing more rapid development and a substantially reduced failure rate".
"The addition of peakfinder chemogenetic arrays, through development of our in-house capabilities, signifies a big step forward in supporting our customers' drug discovery challenges", said Ray Fisher, Peakdale commercial director.
"It draws upon our core strength in organic synthesis, complemented with Cadd and medicinal chemistry expertise."
